1 Title page

-
1
_

- 3 Title
- 4 Intronic FGF14 GAA repeat expansions are a common cause of downbeat nystagmus syndromes: frequency,
- 5 phenotypic profile, and 4-aminopyridine treatment response
- 6

7 Authors

- 8 David Pellerin^{1,2}; Felix Heindl³; Carlo Wilke^{4,5}; Matt C. Danzi⁶; Andreas Traschütz^{4,5}; Catherine Ashton^{1,7}; Marie-
- 9 Josée Dicaire¹; Alexanne Cuillerier⁸; Giulia Del Gobbo⁸; Kym M. Boycott⁸; Jens Claassen^{9,10}; Dan Rujescu¹¹;
- 10 Annette M. Hartmann¹¹; Stephan Zuchner⁶; Bernard Brais^{1,12,13}; Michael Strupp^{3,*}; Matthis Synofzik^{4,5,*}
- 11

12 Affiliations

- ¹Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University,
- 14 Montreal, QC, Canada
- 15 ²Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for
- 16 Neurology and Neurosurgery, University College London, London, United Kingdom
- ¹⁷ ³Department of Neurology and German Center for Vertigo and Balance Disorders, University Hospital, Ludwig-
- 18 Maximilians University, Munich, Germany
- ⁴Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and
- 20 Center of Neurology, University of Tübingen, Tübingen, Germany
- 21 ⁵German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
- 22 ⁶Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human
- 23 Genomics, University of Miami Miller School of Medicine, Miami, FL, USA
- ⁷Department of Neurology, Royal Perth Hospital, Perth, WA, Australia
- ⁸Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada
- ⁹Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
- ¹⁰MediClin Klinik Reichshof, Reichshof-Eckenhagen, Germany
- 28 ¹¹Department of Psychiatry, Medical University of Vienna, Vienna, Austria

- 29 ¹²Department of Human Genetics, McGill University, Montreal, QC, Canada
- 30 ¹³Centre de Réadaptation Lucie-Bruneau, Montreal, QC, Canada
- 31 *Shared last authors
- 32
- 33 Corresponding author
- 34 Matthis Synofzik, MD
- 35 Professor of Neurology
- 36 Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and
- 37 Center of Neurology, University of Tübingen
- 38 Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany
- 39 Phone: +49-7071-2982060
- 40 Fax: +49-7071-2925001
- 41 matthis.synofzik@uni-tuebingen.de
- 42
- 43 **Running title:** *FGF14* GAA expansions in downbeat nystagmus syndromes

44 Abstract

The cause of downbeat nystagmus (DBN) remains unknown in approximately 30% of patients (idiopathic DBN). Here, we hypothesized that: (i) FGF14 (GAA)_{≥250} repeat expansions represent a frequent genetic cause of idiopathic DBN syndromes, (ii) are treatable with 4-aminopyridine (4-AP), and (iii) FGF14 (GAA)₂₀₀₋₂₄₉ alleles are potentially pathogenic.

49

We conducted a multi-modal cohort study of 170 patients with idiopathic DBN that comprised: in-depth ocular motor, neurological, and disease evolution phenotyping; assessment of 4-AP treatment response, including reanalysis of placebo-controlled video-oculography treatment response data from a previous randomized double-blind 4-AP trial; and genotyping of the *FGF14* repeat.

54

55 Frequency of FGF14 (GAA)₂₅₀ expansions was 48% (82/170) in the entire idiopathic DBN cohort. Additional 56 cerebellar ocular motor signs were observed in 100% (82/82), cerebellar ataxia in 43% (35/82), and extracerebellar 57 features in 21% (17/82) of (GAA)_{>250}-FGF14 patients. Alleles of 200 to 249 GAA repeats were enriched in patients 58 with DBN (12%; 20/170) compared to controls (0.87%; 19/2,191; OR, 15.20; 95% CI, 7.52-30.80; p=9.876e-14). 59 The phenotype of (GAA)₂₀₀₋₂₄₉-FGF14 patients closely mirrored that of (GAA)_{>250}-FGF14 patients. (GAA)_{>250}-60 FGF14 and $(GAA)_{200-249}$ -FGF14 patients had a significantly greater clinician-reported (80% vs 31%; p=0.0011) and 61 self-reported (59% vs 11%; p=0.0003) response rate to 4-AP treatment compared to (GAA)_{<200}-FGF14 patients. 62 This included a treatment response with high relevance to everyday living, as exemplified by an improvement of 2 63 FARS stages in some cases. Placebo-controlled video-oculography data of four (GAA)=250-FGF14 patients 64 previously enrolled in a 4-AP randomized double-blind trial showed a significant decrease in slow phase velocity of 65 DBN with 4-AP, but not placebo.

66

This study shows that *FGF14* GAA repeat expansions are a highly frequent genetic cause of DBN syndromes, especially when associated with additional cerebellar features. Moreover, they genetically stratify a subgroup of patients with DBN that appear to be highly responsive to 4-AP, thus paving the way for a "theranostics" approach in DBN syndromes.

71

- 72 Keywords: SCA27B; natural history; repeat expansion disorder; placebo-controlled trial; theranostics; genome-
- vide association study

74 Introduction

Downbeat nystagmus (DBN) is the most common form of acquired persisting nystagmus and is characterized by a pathological slow upward drift of the eyes followed by a corrective downward saccade.^{1,2} In most cases it is caused by a hypofunction of the cerebellar flocculus/paraflocculus or their projections, which leads to disinhibition of the superior vestibular nuclei neurons, resulting in spontaneous slow upward eye drift.³⁻⁶ DBN is a common feature of the allelic disorders spinocerebellar ataxia 6 and episodic ataxia type 2, while it is infrequently observed in other forms of spinocerebellar ataxia.⁷⁻¹⁰ Despite the numerous known genetic and acquired etiologies,^{1,2} the cause of DBN remains unknown in approximately 30% of cases (idiopathic DBN).²

82

The recent identification of an association between a variation (rs72665334) in intron 1 of the fibroblast growth factor 14 (*FGF14*) gene and idiopathic DBN in a genome-wide association study (GWAS)¹¹ and of a dominantly inherited (GAA)_{≥ 250} repeat expansion in intron 1 of *FGF14* as the cause of spinocerebellar ataxia 27B (SCA27B) / GAA-*FGF14* ataxia,^{12,13} a late-onset slowly progressive cerebellar syndrome that is frequently associated with DBN,^{12,14} provided evidence for a potential link between *FGF14* and DBN.^{12,14,15} Furthermore, 4-aminopyridine (4-AP), a proven effective symptomatic treatment for DBN,^{16,17} has shown promising benefits to reduce the frequency and severity of ataxic symptoms in previous small series of patients with GAA-*FGF14* ataxia.^{12,14,18}

90

Based on these findings, we hypothesized that FGF14 (GAA)_{≥250} repeat expansions are a frequent monogenic cause of idiopathic DBN syndromes, which are treatable with 4-AP, and are in disequilibrium with the genome-wide significant rs72665334 variant previously identified by GWAS. Moreover, we systematically studied the phenotype and 4-AP treatment response of patients with DBN carrying an *FGF14* (GAA)₂₀₀₋₂₄₉ allele, providing preliminary evidence that these so-called "intermediate" alleles might be pathogenic.

96

97 Methods

98 **Patient Enrollment**

We enrolled a consecutive series of 219 index patients with suspected DBN referred to the Department of Neurology or the German Center for Vertigo and Balance Disorders at the LMU Hospital in Munich, Germany, between 2012 and 2020. Etiologic evaluation of DBN was performed through a detailed medical history, assessment of drug abuse,

102 comprehensive neurological examination, laboratory tests, and brain imaging by MRI or CT scan. Genetic screening 103 for episodic ataxias and spinocerebellar ataxias was performed in select patients with a suggestive phenotype when 104 deemed appropriate by the clinician. Patients were excluded from the study if: (i) no DNA was available for genetic 105 screening (n=2), (ii) DBN was not objectified on neuro-ophthalmological examination after review of the medical 106 records (n=11), or (iii) a competing etiology for DBN was identified (n=36). The final study cohort comprised 170 107 patients with a diagnosis of idiopathic DBN (Fig. 1). Part of this patient cohort (n=80) has previously been reported 108 in the idiopathic DBN GWAS.¹¹ All but three patients (one [GAA]_{>250}-FGF14 and two [GAA]_{<200}-FGF14) were of 109 self-reported European descent. The three non-European patients were of Turkish descent. This study was approved 110 by the ethics committees of the LMU Munich, the Montreal Neurological Hospital-Institute, and Clinical Trials 111 Ontario and was carried out in accordance with the Declaration of Helsinki. We obtained written informed consent 112 from all the participants in this study.

113

114 Deep Phenotyping

115 All patients underwent at least one comprehensive neurological and ocular motor examination. Deep phenotyping 116 was performed by systematically reassessing all medical records using a standardized data sheet while being blind to 117 the GAA-FGF14 genotype. Functional impairment was assessed in terms of the need for mobility aids and by means 118 of the Friedreich Ataxia Rating Scale (FARS) functional stage (0=normal; 1=minimal signs on examination; 119 2=minimal disability; 3=mild disability; 4=moderate disability, requires a walker; 5=severe disability, confined but 120 can navigate a wheelchair; 6=total disability).¹⁹ Results of routine brain MRI and nerve conduction studies were 121 available for review in 70% (119/170) and 18% (31/170) of patients, respectively. Ancillary assessment of vestibular 122 function was obtained in 94% (159/170) of patients using bithermal caloric stimulation (n=147), video head impulse 123 test (vHIT; n=100), and rotatory chair test (n=1). Posturography (Kistler platform, Kistler Instrumente AG) was 124 obtained in 59% (100/170) of patients and results were analyzed with an artificial neural network.²⁰

125

Patients were stratified in one of four phenotypic clusters based on the presence of additional cerebellar and/or extracerebellar signs: pure DBN, DBN plus additional isolated cerebellar ocular motor signs (DBN+COM), DBN plus cerebellar ataxia (DBN+CA), and DBN plus cerebellar and extracerebellar features (DBN+EC), which included bilateral vestibulopathy (BVP) and/or polyneuropathy. Along with the cerebellar system, the vestibular and sensory

systems appear to be preferentially impaired in GAA-FGF14 ataxia.^{14,15} Additional cerebellar ocular motor signs 130 131 were defined by the presence of at least one of: saccadic pursuit, dysmetric saccades, gaze-evoked nystagmus, 132 rebound nystagmus, or impaired visual fixation suppression of the vestibulo-ocular reflex (VOR). Cerebellar ataxia 133 was defined by the presence of cerebellar dysarthria, dysdiadochokinesia, intention tremor, or, when available, 134 evidence of cerebellar involvement on posturography. BVP was diagnosed as per the consensus criteria of the 135 Bárány Society requiring the documentation of bilaterally reduced or absent angular VOR function by caloric 136 stimulation, vHIT, or rotatory chair.²¹ Polyneuropathy was diagnosed on nerve conduction studies (excluding focal 137 entrapment neuropathies) or clinically defined by the combination of significantly decreased vibration sense at the ankles (\leq 3/8 on the Rydel-Seiffer scale) and decreased or absent ankle reflexes.²² 138

139

140 Assessment of Treatment Response to 4-aminopyridine

141 Assessment of treatment response to 4-AP was performed by two independent approaches. (1) Open-label real-142 world treatment response data. Information on clinician-reported and patient-reported response to 4-AP treatment 143 (fampridine 10mg twice a day) was collected (available for 83 patients). As all patients from this study who were 144 treated with 4-AP received the drug before the discovery of GAA-FGF14 ataxia, the assessment of treatment 145 response was naturally blind to the underlying GAA-FGF14 genotype. Patients were routinely evaluated 1 to 3 146 months after initiating treatment with 4-AP. Patient-reported responses were assessed based on their global 147 impressions of the impact of treatment on their neurological functioning. Clinician-reported responses were 148 evaluated based on the clinician's global impression from neurological and neuro-ophthalmological examinations. 149 (2) Double-blind placebo-controlled clinical trial data. Four patients with DBN had been part of an earlier placebo-150 controlled randomized double-blind trial assessing the efficacy of 4-AP in a cohort of 27 patients with DBN.¹⁶ All 151 four patients, now known via the current study to carry an *FGF14* (GAA)_{≥ 250} expansion, were genetically 152 undiagnosed at the time of the original trial.¹⁶ Due to unavailability of DNA, the genetic status of the remaining 23 153 patients who took part in the 4-AP trial remains unknown. As part of the trial, patients had received 5 mg of 4-AP 154 (or placebo) four times a day for 3 days and 10 mg of 4-AP (or placebo) four times a day for 4 days. Randomization 155 resulted in all four patients receiving active treatment first, then placebo, separated by a 1-week washout. 156 Assessments were done before the first, 60 min after the first, and 60 min after the last drug administration, 157 measuring the slow phase velocity (SPV) of DBN by video-oculography (degrees/second) as primary outcome.

158

159 Genetic Screening for *FGF14* Repeat Expansions

160 The *FGF14* repeat locus was genotyped by capillary electrophoresis of fluorescent long-range PCR amplification 161 products and bidirectional repeat-primed PCRs, as described previously.²³ Expansions of at least 250 GAA repeat 162 units were considered pathogenic.^{12,13} Alleles of 200 to 249 GAA repeat units were analyzed separately as their 163 pathogenicity has recently been suggested.²⁴

164

165 Genotyping of the *FGF14* rs72665334 Variant

166 The rs72665334 C>T variant in intron 1 of *FGF14* (GRCh38, chr13:102,150,076) was found to be associated with 167 idiopathic DBN in 106 patients in a recent GWAS.¹¹ Genotyping data were previously generated using the 168 HumanOmniExpress-24 array and data for the rs72665334 variant with call rate probability >70% were extracted for 169 73 patients enrolled in this study.

170

To assess whether the rs72665334 variant is in disequilibrium with the *FGF14* GAA repeat expansion at a population level, we also genotyped the rs72665334 variant by Sanger sequencing in an independent and ethnically distinct cohort of 37 French-Canadian index patients with GAA-*FGF14* ataxia and DBN. PCR reactions were performed in a 24μ L volume using the Qiagen Taq DNA polymerase kit (catalog no. 201209, Qiagen) with 0.125mM dNTPs, 1μ M of forward and reverse primers (forward primer: 5'-GCCCCTGTTCTAAAGCCTCT-3'; reverse primer: 5'-GATCGTCCAGCCACATCTCT-3'), and 240ng of genomic DNA. Sanger sequencing of PCR amplification products was performed using the ABI 3730*xl* Analyzer (Applied Biosystems).

178

179 Statistical Analysis

We assessed differences between groups with the non-parametric Mann-Whitney U test for continuous variables and the Fisher's exact test for categorical variables. Effect sizes are reported as odds ratio (OR) with 95% confidence intervals (CIs). The non-parametric Kruskal-Wallis test was used for comparisons between multiple groups. Correlations were calculated using the Pearson's correlation coefficient or the Spearman's rank correlation coefficient. The Kaplan-Meier method was used to analyze disease-free survival. Cross-sectional FARS stages measured off 4-AP were analyzed by linear regression as a function of disease duration, age, and the expansion size.

To estimate the longitudinal progression of disability over the disease course, we used a linear mixed-effects model fitted by the restricted maximum likelihood method accounting for disease duration as fixed effect and with random intercepts and random slopes. We re-analyzed treatment effects of 4-AP and placebo by means of a mixed-effect analysis of repeated measures, with post-hoc comparison by uncorrected Fisher's least significant difference. We analyzed the data in R (version 4.3) and GraphPad Prism 9.3. *P* value of <0.05 was considered significant, using the Benjamini-Hochberg method to correct for multiple comparisons. All analyses were two-sided.

192

193 Data Availability

194 Individual deidentified patient data may be shared at the request of any qualified investigator upon reasonable 195 request. No consent for open sharing has been obtained.

196

197 Results

198 Frequency of FGF14 GAA Repeat Expansions in Downbeat Nystagmus Syndromes

199 A total of 170 index patients with a diagnosis of idiopathic DBN formed the final study cohort and were screened 200 for FGF14 GAA repeat expansions (Figs. 1 and 2A). We identified 82 patients (48%) who carried an FGF14 201 (GAA)_{>250} expansion (median size of expansion, 324 repeat units; range, 250-516), including one patient carrying 202 biallelic GAA expansions of 280 and 313 repeat units. Alleles of 200 to 249 repeat units were identified in 12% of 203 patients (20/170; median size of allele, 234 repeat units; range, 207-249), compared to 0.87% in 2,191 previously 204 reported control individuals²⁵ (19/2,191), suggesting an enrichment of this population of alleles in patients with 205 DBN (OR, 15.20; 95% CI, 7.52-30.80; Fisher's exact test, p=9.876e-14). Two patients carried a likely non-206 pathogenic^{24,26} (GAAGGA)_n expansion of 319 and 335 triplet repeat units equivalent, respectively.

- 207
- The frequency of *FGF14* (GAA)_{≥ 250} expansions in DBN syndromes stratified by phenotype was 56% (42/75) for DBN plus additional isolated cerebellar ocular motor signs, 72% (23/32) for DBN plus cerebellar ataxia, 30% (17/56) for DBN plus cerebellar ocular motor signs and/or ataxia and extracerebellar features, which included BVP
- 211 and/or polyneuropathy, and 0% (0/7) for pure DBN (Fig. 2B).
- 212

213 Phenotype and Discriminative Features of (GAA)>250-FGF14-related Downbeat Nystagmus Syndromes

Table 1 summarizes the baseline characteristics and clinical features of patients carrying a $(GAA)_{\geq 250}$ expansion, a $(GAA)_{200,249}$ allele, and a $(GAA)_{<200}$ allele.

216

217 Symptoms in (GAA)_{>250}-FGF14 patients with DBN started at a median age of 67 years (range, 30-81). The most 218 common presenting symptom was gait unsteadiness (89%; 72/81), followed by visual disturbances (37%; 30/81), 219 such as diplopia, oscillopsia, or visual blurring, vertigo and/or dizziness (20%; 16/81), and, rarely, dysarthria (1%; 220 1/81) (Fig. 2C). We observed a weak inverse correlation between the age at onset and the size of the repeat 221 expansion (74 patients; Pearson's r, -0.30; $R^2=0.09$; p=0.01) (Fig. 2D). Family history for DBN or ataxia was 222 positive in 31 patients (38%), of whom 26 had evidence of autosomal dominant inheritance. In keeping with the 223 likely reduced male transmission of the disease due to contraction of the FGF14 repeat locus upon paternal 224 transmission,^{12,25} we observed that only 2 of 26 dominantly inherited cases (8%) were paternally inherited.

225

226 The median age and disease duration at last examination were 73 years (range, 40-92) and 6 years (range, 0-26.5), 227 respectively. Additional cerebellar ocular motor signs were observed in 100% (82/82), cerebellar ataxia in 43% 228 (35/82), and extracerebellar features in 21% (17/82) of (GAA)_{>250}-FGF14 patients (Fig. 2E). Cerebellar ocular 229 motor signs comprised - in decreasing order of frequency - saccadic pursuit (99%; 80/81), impaired visual fixation 230 suppression of the VOR (86%; 64/74 in patients without BVP), gaze-evoked nystagmus (70%; 57/82), dysmetric 231 saccades (28%; 22/79), and rebound nystagmus (20%; 16/82). Signs of cerebellar ataxia included dysmetria of upper 232 limbs (46%; 16/35), dysdiadochokinesia (47%; 15/32), dysarthria (35%; 12/34), and intention tremor (11%; 4/35). 233 Cerebellar involvement reflected by ~3Hz titubation was identified in 18 of 55 patients (33%) on posturography. 234 Brain MRI of eight patients showed cerebellar atrophy (13%; 8/60), which was limited to the vermis in three 235 patients and extended to the hemispheres in five patients. Two patients with discrete pan-cerebellar atrophy showed 236 no signs of ataxia on examination.

237

The subgroup of $(GAA)_{\geq 250}$ -*FGF14* patients with DBN plus cerebellar ocular motor signs and/or ataxia and extracerebellar features comprised nine patients with polyneuropathy, six patients with BVP, and two patients with polyneuropathy plus BVP (**Fig. 2E**). Polyneuropathy and BVP occurred more frequently in patients with cerebellar ataxia (71%; 12/17) compared to patients exhibiting only cerebellar ocular motor signs (29%; 5/17) (**Fig. 2E**).

Polyneuropathy was diagnosed on nerve conduction studies in seven patients and clinically in four patients. Results of nerve conduction studies were consistent with length-dependent sensorimotor axonal neuropathy in six patients and sensory neuropathy in one patient. BVP was diagnosed in 8 of 79 patients (10%) by caloric stimulation (n=1) and vHIT (n=7). Disease duration at time of vestibular assessment differed significantly between patients with and without BVP (median, 14 vs 4 years; Mann-Whitney U test, p=0.0018).

247

248 To identify discriminative features of DBN syndromes in $(GAA)_{>250}$ -FGF14 patients, we compared their phenotypic 249 features to that of (GAA)_{<200}-FGF14 patients (**Table 1**). Both groups did not differ significantly in terms of disease 250 duration, baseline characteristics, functional impairment, and symptoms. Impairment of the visual fixation 251 suppression of the VOR was strongly associated with (GAA)_{>250}-FGF14 DBN syndromes (86% vs 50%; OR, 6.29; 252 95% CI, 2.45-17.24; Fisher's exact test, p=2.089e-05, q=6.685e-04). In keeping with the lower frequency of FGF14 253 repeat expansions in patients with DBN plus extracerebellar features, impaired vibration at the ankles (14% vs 37%; 254 OR, 0.28; 95% CI, 0.11-0.66; Fisher's exact test, p=0.002, q=0.018) and BVP (10% vs 32%; OR, 0.24; 95% CI, 255 0.08-0.63; Fisher's exact test, p=0.001, q=0.018) were significantly less common in (GAA)_{>250}-FGF14 than in 256 (GAA)_{<200}-FGF14 patients. Furthermore, in the subset of patients in whom BVP was objectified on vHIT, the mean 257 VOR gain was significantly higher (values of >0.6 are considered normal) in (GAA)>250-FGF14 compared to 258 $(GAA)_{<200}$ -FGF14 patients (0.44 ±0.10 vs 0.18 ±0.17; Mann-Whitney U test, p=0.006, q=0.0496), despite no 259 significant difference in disease duration between the groups (median, 14.5 vs 8 years; Mann-Whitney U test, 260 p=0.1512). These results suggest that BVP occurs late in the course of (GAA)_{>250}-FGF14-related DBN syndromes 261 and remains mild.

262

263 Disease Progression in (GAA)_{>250}-FGF14-related Downbeat Nystagmus Syndromes

We used a Kaplan-Meier survival analysis to model the age at disease onset of $(GAA)_{\geq 250}$ -*FGF14* patients, estimating their probability of remaining disease-free over time (**Fig. 3A**). Survival until disease onset in $(GAA)_{\geq 250}$ -*FGF14* patients did not significantly differ between the three main phenotypic subgroups (median age at onset, 67 years [33-80] for DBN+COM vs 67 years [36-81] for DBN+CA vs 66 years [30-78] for DBN+EC; Cox-Mantel test, $X^2(2)=0.1267$; *p*=0.939). However, disease duration at last examination was significantly longer in patients with DBN plus cerebellar and extracerebellar features (median, 4.25 years [0-16] for DBN+COM vs 6 years [1-22] for

270 DBN+CA vs 9 years [3-26.5] for DBN+EC; Kruskal-Wallis test, p=0.014) (**Fig. 3B**), suggesting that extracerebellar 271 features may develop later in the disease course.

272

273 We also studied the evolution of key symptoms in $(GAA)_{>250}$ -FGF14 patients in relation to gait impairment (Fig. 274 **3C**). Episodic symptoms (median, 0 year; range, -6-5) and oscillopsia (0.75 year; -8-5) manifested concurrently with 275 gait impairment in most patients. However, episodic symptoms and oscillopsia preceded gait impairment in 10% 276 (1/10) and 11% (3/28) of patients for whom information on age at onset of these features was available, respectively. 277 In comparison, fine motor impairment (5 years; 0-8), speech impairment (4 years; 0-10), and falls (2 years; 0-12) 278 developed later in the disease course, consistent with the findings from a recent progression study.¹⁴ Sixteen patients 279 (20%) eventually required a walking aid after a median disease duration of 4 years (range, 0-13), including three 280 patients (4%) who became wheelchair dependent after a median disease duration of 8 years (range, 7-12). Further to 281 this analysis, we observed that BVP developed at a significantly later stage in the disease compared to cerebellar 282 atrophy and neuropathy (median disease duration at first occurrence, 4 years [1-7] for cerebellar atrophy vs 3 years 283 [1-6] for polyneuropathy vs 10 years [3-21.5] for BVP; Kruskal-Wallis test, p=0.004) (Fig. 3D).

284

285 The progression of functional disability in (GAA)-250-FGF14 patients was assessed by means of the FARS 286 functional staging (Fig. 4). At time of last examination, the median FARS stage measured off 4-AP was 3 (range, 2-287 5), indicating a mild level of disability. We found no association between the FARS functional stage and disease 288 duration (73 patients; Spearman's rho, 0.194; p=0.10) (Fig. 4A). Neither age, disease duration, or expansion size 289 was associated with the cross-sectional FARS stage in a multiple linear regression model (F(3.69)=2.602, adjusted 290 $R^2=0.06$, p=0.059; age, b=0.017, p=0.111; disease duration, b=0.027, p=0.151; expansion size, b=-0.001, p=0.527). 291 Analysis of the cross-sectional and longitudinal FARS stage data revealed that half of patients (27/54) displayed at 292 least mild disability within the first five years of disease onset. However, disability remained at most mild in the 293 majority of patients (86%, 63/73) even after more than 25 years of disease duration. This observation was further 294 supported by longitudinal data in 40 patients (148 observations) showing an overall slow intra-individual increase of 295 0.10 FARS stage per year of disease (standard error, 0.02 by linear mixed-effects model) (Fig. 4B). While disease 296 evolved relatively slowly in most patients, inspection of individual disability progression trajectories revealed inter-297 individual variability in rates of progression (Fig. 4B). Concurrent medical conditions substantially contributed to

298 disability burden in two patients. One patient became wheelchair-bound following a complicated medical admission. 299 However, this patient also carried biallelic expansions (280 and 313 repeat units) which may have contributed to the 300 faster disability progression. The second patient, carrying alleles of 218 and 270 repeat units, became wheelchair-301 bound following a hip fracture. 302 303 (GAA)₂₀₀₋₂₄₉-FGF14 Patients have a Similar Clinical Phenotype and Disease Evolution as (GAA)_{>250}-FGF14 304 **Patients** 305 While previous studies have established a preliminary pathogenic threshold of at least 250 GAA repeat units,^{12,13} the 306 pathogenic potential of (GAA)₂₀₀₋₂₄₉ alleles has recently been suggested following the identification of a family with 307 late-onset slowly progressive ataxia in which (GAA)₂₀₀₋₂₄₉ alleles and (GAA)₂₂₅₀ expanded alleles segregated with 308 disease.²⁴ Alleles of 200 to 249 GAA repeat units were significantly enriched in patients with DBN compared to 309 controls (12% vs 0.87%; OR, 15.20; 95% CI, 7.52-30.80; Fisher's exact test, p=9.876e-14), thus providing further

- 310 support for their potential pathogenicity.
- 311

312 We next aimed to characterize the phenotype of $(GAA)_{200-249}$ -FGF14 patients to assess whether it resembled that of 313 (GAA)_{>250}-FGF14 patients (Table 1). (GAA)₂₀₀₋₂₄₉-FGF14 patients did not significantly differ from (GAA)_{>250}-314 FGF14 patients in terms of baseline characteristics, symptoms, clinical signs, and progression of functional 315 disability. In comparison, impairment of the visual fixation suppression of the VOR (indicating an involvement of 316 the fixation system), which was strongly associated with (GAA)_{>250}-FGF14-related DBN syndromes, was 317 significantly more common in $(GAA)_{200-249}$ -FGF14 patients compared to $(GAA)_{<200}$ -FGF14 patients (94%, 16/17 vs 318 50%, 23/46; OR, 15.45; 95% CI, 2.07-696.97; Fisher's exact test, p=0.001; q=0.037), but not different from 319 $(GAA)_{>250}$ -FGF14 patients (94%, 16/17 vs 86%, 64/74; Fisher's exact test, p=0.682; q=1.000).

320

Association of the rs72665334 Variant with FGF14 (GAA)≥250 Expansions in Patients with Downbeat Nystagmus

323 A recent GWAS has identified an association between DBN and the *FGF14* rs72665334 C>T variant in 106 patients 324 (**Fig. 5A**).¹¹ This same variant, which has an allele frequency of ~7% in the European population (1000 Genomes 325 Project²⁷), was also found to be part of a disease haplotype shared by three Australian patients with GAA-*FGF14*

326 ataxia in a previous study.¹³ Given the frequent occurrence of DBN in GAA-FGF14 ataxia, we therefore 327 hypothesized that the rs72665334 variant might be in disequilibrium with the FGF14 GAA repeat expansion, which 328 is located ~11kb away (Fig. 5A). In the DBN cohort, we observed that a significantly greater proportion of patients 329 with a C|T or T|T genotype carried an FGF14 (GAA)_{>250} expansion compared to an FGF14 (GAA)_{<200} allele (54%, 330 19/35 vs 14%, 4/29; OR, 7.18; 95% CI, 1.91 to 34.43; Fisher's exact test p=0.0014) (Fig. 5B). Similarly, we also 331 found that 38% of patients (14/37) from an independent and ethnically distinct cohort of 37 French-Canadian index 332 patients with GAA-FGF14 ataxia and DBN had a C/T or T/T rs72665334 genotype. To assesses whether the 333 rs72665334 variant is in disequilibrium with the FGF14 (GAA)_{>250} expansion at a population level, we compared 334 the frequency of the C|T and T|T genotypes in 503 European controls from the 1000 Genomes Project and 72 335 patients with GAA-FGF14 ataxia and DBN (35 patients from this study and 37 French-Canadian patients). The C|T 336 and T/T genotypes were significantly more frequent in patients with DBN carrying an FGF14 (GAA)=250 expansion 337 compared to controls (46%, 33/72 vs 12%, 60/503; OR, 6.22; 95% CI, 3.51 to 11.02; Fisher's exact test, p=1.063e-338 10) (Fig. 5C). Together, these results show that the rs72665334 variant is in disequilibrium with the FGF14 GAA 339 repeat expansion. However, its absence in 54% of (GAA)_{>250}-FGF14 patients suggests that FGF14 GAA repeat 340 expansions may arise on distinct haplotype backgrounds.

341

342 Treatment Response to 4-Aminopyridine

343 Open-label real-world treatment response data. We assessed the response to 4-AP treatment in patients with DBN 344 stratified by FGF14 genotype (open-label treatment as part of routine clinical care). 81% of (GAA)_{>250}-FGF14 345 patients (66/81), 61% of (GAA)₂₀₀₋₂₄₉-FGF14 patients (11/18), and 56% of (GAA)_{<200}-FGF14 patients (37/66) had 346 previously received 4-AP. Treatment response for all patients had been recorded before the discovery of GAA-347 FGF14 ataxia and, therefore, both clinicians and patients were naturally blind to the underlying GAA-FGF14 348 genotype ("real-world double-blind" to genotype). A clinician-reported treatment response was recorded for 81% of 349 (GAA)_{>250}-FGF14 patients (29/36; improvement of ocular motor signs, including DBN: 24 patients; and gait: 14 350 patients), 80% of (GAA)₂₀₀₋₂₄₉-FGF14 (4/5; ocular motor signs: 2; gait: 3), and 31% of (GAA)₂₀₀-FGF14 patients 351 (5/16; ocular motor signs: 3; gait: 2) (Fig. 6A). A patient-reported benefit was recorded for 59% of (GAA)=250-352 FGF14 (29/49; improvement of visual symptoms: 14 patients; and gait: 17 patients), 60% of (GAA)₂₀₀₋₂₄₉-FGF14 353 (3/5; visual symptoms: 2; gait: 2), and 11% of $(GAA)_{<200}$ -FGF14 patients (2/19; visual symptoms: 1; gait: 1) (Fig.

354 **6B**). $(GAA)_{\geq 250}$ -FGF14 and $(GAA)_{\geq 00-249}$ -FGF14 patients had a significantly greater clinician-reported (80% vs 355 31%; OR, 8.63; 95% CI, 2.08 to 41.96; Fisher's exact test p=0.0011) and patient-reported (59% vs 11%; OR, 11.96; 356 95% CI, 2.45 to 117.27; Fisher's exact test p=0.0003) response rate to 4-AP treatment compared to (GAA)_{<200}-357 FGF14 patients. To next evaluate the effect of 4-AP on disability, we examined the FARS disability stages assessed 358 on and off 4-AP. Data were available for seven (GAA)_{>250}-FGF14 and two (GAA)₂₀₀₋₂₄₉-FGF14 patients (Fig. 7). 359 Remarkably, the FARS stages for all nine patients were invariably lower, by up to 2 stages, while on 4-AP 360 compared to off 4-AP. The therapeutic benefit of 4-AP was further evidenced by the clear association between drug 361 intake and improvement of disability in four patients in whom stopping the drug led to an increase in disability (Fig. 362 7). Given the average progression of 0.10 FARS stage per year of disease (Fig. 4B), an improvement of 1 FARS 363 stage on 4-AP treatment might be considered equivalent to "reversing" the disease progression by approximately 10 364 years. These results, which need confirmation in randomized placebo-controlled trials, suggest that the GAA-FGF14 365 genotype status stratifies a subgroup of patients with DBN who are high responders to 4-AP. The response to 4-AP, 366 whether reported by the clinician or the patient, may also be a useful clinical sign to increase suspicion for GAA-367 FGF14 disease, given its positive predictive value of 88% (95% CI, 74-96%) for (GAA)=250-FGF14 status and 89% 368 (95% CI, 76-96%) for combined (GAA)_{>250}-FGF14 and (GAA)₂₀₀₋₂₄₉-FGF14 statuses.

369

370 Double-blind placebo-controlled clinical trial data. We next analyzed in a first preliminary probing approach 371 whether the effects of 4-AP treatment in GAA-FGF14-related DBN could be validated not only in open-label 372 assessments, but also in double-blind, placebo-controlled randomized treatment assessments. For this purpose, we 373 re-analyzed placebo-controlled video-oculography data of four patients with DBN – now known to be (GAA)_{>250}-374 FGF14 – from a previous randomized double-blind trial.¹⁶ In addition to being double-blind, all trial assessments 375 were blinded to the underlying GAA-FGF14 genotype, which was not discovered until after the trial. The absolute 376 value of the SPV decreased under treatment with 4-AP (F(2,6) = 6.31, p=0.033), but not under placebo (F(2,5) =377 0.45, p=0.660) (Fig. 6C). The decrease in SPV was significant 60 min after administration of a single dose of 5 mg 378 of 4-AP compared to intra-individual baseline measurements (least squares mean difference: 2.63° /s, p=0.014), and 379 persisted under a stable dose of 40 mg of 4-AP daily (least squares mean difference: 1.97°/s, p=0.043). This effect 380 corresponds to relative reductions (improvements) of SPV by 38-109% after a single dose, and 32-99% under stable 381 treatment with 4-AP (Fig. 6D).

382

383 Discussion

This study tested the hypothesis that FGF14 (GAA)_{≥ 250} repeat expansions are a recurrent cause of idiopathic DBN syndromes, where DBN may be the presenting phenotype of a wider GAA-*FGF14*-related neurological disease spectrum. Our findings identify *FGF14* (GAA)_{≥ 250} repeat expansions as a highly frequent monogenic cause of DBN, particularly when associated with additional cerebellar features. Through systematic in-depth phenotyping, we characterized the disease evolution of (GAA)_{≥ 250}-*FGF14*-related DBN and its treatment response to 4-AP. Additionally, we explored the phenotypic and 4-AP treatment response characteristics of patients with *FGF14* (GAA)₂₀₀₋₂₄₉ alleles, whose pathogenicity has recently been suggested.

391

392 The cause of DBN remains unknown in approximately 30% of cases (idiopathic DBN).^{1.2} Identifying genetic causes 393 for these cases has proven challenging. We now show that FGF14 (GAA)_{>250} repeat expansions account for almost 394 50% of cases of previously unexplained DBN in a large and strictly consecutive cohort of European patients. 395 Dominantly inherited FGF14 GAA repeat expansions have recently been shown to be a common cause of spinocerebellar ataxia (SCA27B), which is associated with DBN in up to 40-60% of patients.^{12,14} However, the high 396 397 frequency of FGF14 (GAA)_{>250} repeat expansions in patients with a predominantly sporadic non-ataxic DBN 398 presentation was unexpected. One explanation may be that DBN is a milder phenotypic presentation of GAA-399 FGF14 disease, in which overt cerebellar ataxia and other multisystemic involvement can be absent (or, in some 400 cases, develop later in the disease course). Our results further suggest that genetic testing for FGF14 GAA repeat 401 expansion should now become part of the diagnostic work-up of patients with idiopathic DBN.

402

By screening a cohort of patients with idiopathic DBN, our study closes a gap in the delineation of the phenotypic spectrum and evolution of GAA-*FGF14* disease. The identification of additional floccular/parafloccular cerebellar ocular motor signs in all $(GAA)_{\geq 250}$ -*FGF14* patients with DBN indicates that the basic dysfunction arises from this cerebellar region and that pure DBN is an uncommon manifestation in GAA-*FGF14* disease. Furthermore, the observation of DBN and ocular motor signs manifesting up to 8 years prior to the development of gait impairment suggests that such signs may present in isolation early in the disease course. However, the recurrent identification of *FGF14* expansions in patients with DBN plus additional isolated cerebellar ocular motor signs but without overt

410 ataxia despite disease duration of up to 16 years raises the possibility that GAA-*FGF14* disease may remain limited 411 to the cerebellar ocular motor system without broader cerebellar involvement in a subset of patients. This indicates 412 that cerebellar ataxia is not a universal and mandatory feature of GAA-*FGF14* disease and that ocular motor signs 413 and ataxia may each represent different features along a continuum of variable cerebellar involvement. Future 414 natural history studies will be needed to determine whether cerebellar ataxia eventually develops in all patients. 415 Nevertheless, the identification of a more limited phenotype in a sizeable number of patients suggests that the 416 overall frequency of GAA-*FGF14* disease may even be higher than previously estimated.

417

418 While BVP has been suggested to be a recurrent feature of GAA-FGF14 disease,¹⁵ our study is the first to provide 419 an estimate of the frequency and temporal evolution of BVP in a large and phenotypically unselected cohort of 420 patients with GAA-FGF14 disease. Ancillary vestibular assessment performed in more than 95% of (GAA)-250-421 FGF14 patients documented BVP in 10% of them. BVP appears to be a late feature in GAA-FGF14 disease 422 compared to cerebellar ataxia, as it developed on average more than 10 years after disease onset. In addition to being 423 significantly less frequent in $(GAA)_{>250}$ -FGF14 compared to $(GAA)_{<200}$ -FGF14 DBN syndromes, BVP tended to 424 remain relatively mild in GAA-FGF14-related DBN syndromes despite prolonged disease duration. The origin of 425 the vestibular pathology in GAA-FGF14 disease is yet to be established, although a central etiology may be more 426 likely given the absence of significant involvement of the peripheral nervous system in this disease.

427

While previous studies of patients with SCA27B have shown rates of cerebellar atrophy ranging from 60 to 100%,^{12,14} only 13% of $(GAA)_{\geq 250}$ -*FGF14* patients with DBN exhibited cerebellar atrophy (mainly of the vermis). This finding might stem from our cohort's main inclusion criterion being DBN, not cerebellar ataxia, resulting in over half of the patients displaying no overt ataxia. Moreover, the median disease duration at time of brain MRI in our DBN cohort was relatively short (4.5 years). Mild cerebellar vermis atrophy can also be challenging to identify on routine MRI and may have been missed.

434

435 Leveraging in-depth phenotyping data, our study identified clinical features discriminating $(GAA)_{\geq 250}$ -*FGF14* from 436 $(GAA)_{<200}$ -*FGF14* DBN syndromes. Of all clinical signs, impairment of the visual fixation suppression of the VOR 437 was most strongly associated with and predictive of $(GAA)_{\geq 250}$ -*FGF14* DBN, also indicating a dysfunction of the

438 cerebellar flocculus/paraflocculus.²⁸ While multiple areas of the brain are involved in gaze stabilization during head 439 movement, the cerebellar flocculus/paraflocculus is critical in modulating the VOR.²⁸ Early dysfunction of these two 440 structures of the vestibulocerebellum, which are also implicated in the pathophysiology of DBN,³⁻⁶ provides a 441 unifying theory for the frequent and early co-occurrence of DBN, impaired VOR cancellation and other eye 442 movement abnormalities, and vertiginous symptoms in GAA-*FGF14* disease.²⁹

443

444 Functional impairment, as captured by the FARS functional disability stage and the need for walking aid, increased 445 relatively slowly with disease duration in (GAA)_{>250}-FGF14 patients, confirming previous reports from patients GAA-FGF14 ataxia.^{12,14} The slow accrual of disability was evidenced by an increase of 0.10 FARS stage per year of 446 447 disease and the need for mobility aids in 20% of patients. However, we observed inter-individual variability in the 448 rate of disability progression among patients, which was at least in part accounted for by concurrent medical 449 illnesses in some patients. These observations strengthen the previous hypothesis from patients with GAA-FGF14 450 ataxia¹⁴ that co-morbid medical illnesses, which are common in elderly populations, must be taken into account 451 when analyzing patient data and planning treatment trials in late-onset diseases like GAA-FGF14 disease as they 452 may alter their natural progression.

453

454 The pathogenic potential of (GAA)₂₀₀₋₂₄₉ alleles has recently been suggested based on the observation of segregation 455 of (GAA)₂₀₀₋₂₄₉ alleles and (GAA)_{>250} expanded alleles with the disease in an affected family with autosomal dominant late-onset slowly progressive cerebellar ataxia.²⁴ Extending this preliminary evidence derived from 456 457 segregation analysis, we now provide quantitative gene burden evidence for this notion by showing a significant 458 enrichment of (GAA)₂₀₀₋₂₄₉ alleles in patients with DBN compared to controls. In addition, as a clinical-phenotypic 459 line of evidence, we observed that impairment of the visual fixation suppression of the VOR and treatment response 460 to 4-AP, both strongly associated with (GAA)>250-FGF14 DBN syndromes, were significantly more common in 461 (GAA)₂₀₀₋₂₄₉-FGF14 than (GAA)₂₀₀-FGF14 patients (but not different from [GAA]₂₅₀-FGF14 patients). It might 462 thus be conceivable that FGF14 (GAA)₂₀₀₋₂₄₉ alleles may cause a milder cerebellar phenotype more commonly 463 manifesting with isolated DBN and cerebellar ocular motor signs. These findings highlight the need to conduct 464 large-scale studies to re-evaluate the pathogenic threshold of GAA-FGF14 disease.

465

466 Our study provides large scale evidence - including a first small set of placebo-controlled data - for the 467 symptomatic benefit of 4-AP in patients with GAA-FGF14 disease. Our findings showed that 4-AP treatment was 468 associated with a clinician-reported treatment response in 80% and a patient-reported meaningful benefit in 59% of 469 $(GAA)_{>250}$ -FGF14 and $(GAA)_{200-249}$ -FGF14 patients. In comparison, such treatment responses were significantly 470 lower in (GAA)_{<200}-FGF14 patients (31% and 11%, respectively). Although these data were collected without 471 knowledge of the GAA-FGF14 genotype but with open-label provision of treatment, the substantially lower 472 response rate to 4-AP treatment in $(GAA)_{<200}$ -FGF14 patients diminishes the likelihood that the observed effects can 473 be largely attributed to placebo. Response to 4-AP in fact represented a strong predictor of (GAA)₂₂₅₀-FGF14 and 474 (GAA)₂₀₀₋₂₄₉-FGF14 status in patients with idiopathic DBN (positive predictive value, 89%). The mechanisms by which 4-AP, a potassium channel blocker,³⁰ ameliorates symptoms in GAA-*FGF14* disease are yet to be established 475 476 although it may involve restoration of cerebellar Purkinje cell rhythmic firing property, as shown in other forms of 477 hereditary ataxia,^{30,31} that is disrupted with the loss of *FGF14* function.^{32,33}

478

479 Albeit still preliminary due to the small sample set, we present the first double-blind (and genotype-blind), placebo-480 controlled randomized treatment data of 4-AP in patients with GAA-FGF14 disease.¹⁶ All four patients for whom 481 DNA was available and who were found to carry an FGF14 (GAA)_{>>50} repeat expansion showed an improvement of 482 SPV of the DBN on 4-AP, but not placebo. This observation bolsters the existing open-label real-world evidence for 483 the treatment efficacy of 4-AP in GAA-FGF14 disease observed in our current cohort and in previous SCA27B 484 cohorts.^{14,18} A larger randomized controlled trial is, nonetheless, warranted to confirm these findings. Our study 485 highlights the potential of video-oculographic assessment of DBN as a responsive outcome measure for treatment. 486 This approach could complement a promising battery of quantitative digital-motor outcomes,¹⁸ including sensor 487 measures of gait and balance, in future trials of 4-AP for GAA-FGF14 disease.

488

The results of our study need to be interpreted in light of some limitations. First, multi-centre studies with patient cohorts with DBN from different ethnic backgrounds are needed to replicate our findings, which were drawn from a single-centre patient cohort of overwhelmingly European background. Such studies are warranted to assess the frequency of *FGF14* GAA repeat expansions in other populations as profiling of the *FGF14* repeat locus in controls of diverse ancestries has shown that larger *FGF14* alleles are less common in non-European persons.^{12,13} Second,

494 future prospective natural history studies in patients with DBN and other non-ataxia predominant phenotypes will be 495 required to accurately track the phenotypic evolution of GAA-*FGF14* disease from its earliest stage and to establish 496 whether a subset of patients never develops overt cerebellar ataxia. Third, our findings of potential pathogenicity of 497 *FGF14* (GAA)₂₀₀₋₂₄₉ alleles are largely preliminary and require validation through additional segregation studies, 498 larger case-control series, and functional studies. Fourth, although we show a treatment effect of 4-AP in several 499 outcomes, including clinician-reported and quantitative digital-motor outcomes, substantiating our real-world 490 treatment response data, the benefits reported herein need validation in a larger randomized placebo-controlled trial.

501

502 In conclusion, we showed that *FGF14* GAA repeat expansions are a highly frequent monogenic cause of DBN 503 syndromes in the European population. Our study suggests that GAA-*FGF14* disease may present along a 504 continuum of variable cerebellar involvement, with some patients exhibiting isolated cerebellar 505 floccular/parafloccular ocular motor signs without overt ataxia, and that *FGF14* (GAA)₂₀₀₋₂₄₉ alleles may be 506 associated with a disease phenotype. It also provides robust and large-scale evidence that the GAA-*FGF14* genotype 507 status defines a subgroup of patients with DBN that appear to be highly responsive to 4-AP, further paving the way 508 toward clinical trials.

509 Author contributions

- 510 Design or conceptualization of the study: DP, CW, BB, MSt, MSy.
- 511 Acquisition of data: DP, FH, CW, MCD, AT, CA, MJD, AC, GDG, KMB, JC, DR, AMH, SZ, BB, MSt, MSy.
- 512 Analysis or interpretation of the data: DP, FH, CW, MCD, AT, CA, MJD, BB, MSt, MSy.
- 513 Drafting or revising the manuscript for intellectual content: DP, FH, CW, MCD, AT, CA, MJD, AC, GDG, KMB,
- 514 JC, DR, AMH, SZ, BB, MSt, MSy.
- 515

516 **Declaration of interests**

- 517 DP reports no disclosures.
- 518 FH reports no disclosures.
- 519 CW reports no disclosures.
- 520 MCD reports no disclosures.
- 521 AT reports no disclosures.
- 522 CA reports no disclosures.
- 523 MJD reports no disclosures.
- 524 AC reports no disclosures.
- 525 GDG reports no disclosures.
- 526 KMB reports no disclosures.
- 527 JC reports no disclosures.
- 528 DR has received grant/research support from Janssen and Lundbeck; he has served as a consultant or on advisory
- 529 boards for AC Immune, Janssen, Roche and Rovi and he has served on speakers bureaus of Janssen and
- 530 Pharmagenetix. He also received honoraria from Gerot Lannacher, Janssen and Pharmagenetix, and travel support
- from Angelini and Janssen, all unrelated to the present manuscript.
- 532 AMH reports no disculosures.
- 533 SZ has received consultancy honoraria from Neurogene, Aeglea BioTherapeutics, Applied Therapeutics, and is an
- 534 unpaid officer of the TGP foundation, all unrelated to the present manuscript.
- 535 BB reports no disclosures.

MSt is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speakers honoraria from Abbott, Auris Medical, Biogen, Eisai, Gru nenthal, GSK, Henning Pharma, Interacoustics, J&J, MSD, NeuroUpdate, Otometrics, Pierre-Fabre, TEVA, UCB, and Viatris. He receives support for clinical studies from Decibel, U.S.A., Cure within Reach, U.S.A. and Heel, Germany. He distributes M-glasses and Positional vertigo App. He acts as a consultant for Abbott, AurisMedical, Bulbitec, Heel, IntraBio, Sensorion and Vertify. He is an investor and share-holder of IntraBio. All are unrelated to the present manuscript.

MSy has received consultancy honoraria from Janssen, Ionis, Orphazyme, Servier, Reata, Biohaven, Zevra, Lilly, GenOrph, and AviadoBio, all unrelated to the present manuscript. MSy is planning a treatment trial of 4-AP in GAA-*FGF14* disease together with Solaxa Inc. as a sponsor, but has not received any type of honoraria or funding from Solaxa.

547

548 Acknowledgments

549 We thank the patients and their families for participating in this study. We thank the Centre d'Expertise et de 550 Services Génome Québec for assistance with Sanger sequencing. DP and GDG hold Fellowship awards from the 551 Canadian Institutes of Health Research (CIHR).

552

553 Study sponsorship and funding

554 This work was supported by the Clinician Scientist program "PRECISE.net" funded by the Else Kröner-Fresenius-555 Stiftung (to CW, AT, and MSy), the grant 779257 "Solve-RD" from the European's Union Horizon 2020 research 556 and innovation program (to MSy), and the grant 01EO 1401 by the German Federal Ministry of Education and 557 Research (BMBF) (to MSt). This work was also supported by the Deutsche Forschungsgemeinschaft (DFG, German 558 Research Foundation) N° 441409627, as part of the PROSPAX consortium under the frame of EJP RD, the 559 European Joint Programme on Rare Diseases, under the EJP RD COFUND-EJP N° 825575 (to MSy, BB and - as 560 associated partner - SZ), the NIH National Institutes of Neurological Disorders and Stroke (grant 2R01NS072248-561 11A1 to SZ), the Fondation Groupe Monaco (to BB), and the Montreal General Hospital Foundation (grant 562 PT79418 to BB). The Care4Rare Canada Consortium is funded in part by Genome Canada and the Ontario 563 Genomics Institute (OGI-147 to KMB), the Canadian Institutes of Health Research (CIHR GP1-155867 to KMB),

- 564 Ontario Research Fund, Genome Quebec, and the Children's Hospital of Eastern Ontario Foundation. The funders
- had no role in the conduct of this study.

566

567 References

- 568 1. Wagner JN, Glaser M, Brandt T, Strupp M. Downbeat nystagmus: aetiology and comorbidity in 117
- 569 patients. J Neurol Neurosurg Psychiatry. Jun 2008;79(6):672-7. doi:10.1136/jnnp.2007.126284
- 570 2. Tran TM, Lee MS, McClelland CM. Downbeat nystagmus: a clinical review of diagnosis and management.
- 571 Curr Opin Ophthalmol. Nov 1 2021;32(6):504-514. doi:10.1097/icu.000000000000802
- 572 3. Pierrot-Deseilligny C, Milea D. Vertical nystagmus: clinical facts and hypotheses. Brain. Jun 2005;128(Pt
- 573 6):1237-46. doi:10.1093/brain/awh532
- 574 4. Kalla R, Deutschlander A, Hufner K, et al. Detection of floccular hypometabolism in downbeat nystagmus
- 575 by fMRI. Neurology. Jan 24 2006;66(2):281-3. doi:10.1212/01.wnl.0000194242.28018.d9
- 576 5. Hüfner K, Stephan T, Kalla R, et al. Structural and functional MRIs disclose cerebellar pathologies in
- 577 11 idiopathic nystagmus. Neurology. Sep 2007;69(11):1128-35. downbeat 578
- doi:10.1212/01.wnl.0000276953.00969.48
- 579 6. Marti S, Straumann D, Büttner U, Glasauer S. A model-based theory on the origin of downbeat nystagmus. 580 Exp Brain Res. Jul 2008;188(4):613-31. doi:10.1007/s00221-008-1396-7
- 581 7. Takahashi H, Ishikawa K, Tsutsumi T, et al. A clinical and genetic study in a large cohort of patients with

582 spinocerebellar ataxia type 6. J Hum Genet. 2004;49(5):256-64. doi:10.1007/s10038-004-0142-7

- 583 8. Yabe I, Sasaki H, Takeichi N, et al. Positional vertigo and macroscopic downbeat positioning nystagmus in 584 spinocerebellar ataxia type 6 (SCA6). J Neurol. Apr 2003;250(4):440-3. doi:10.1007/s00415-003-1020-5
- 585 9. Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology. Jan 13 2004;62(1):17-
- 586 22. doi:10.1212/01.wnl.0000101675.61074.50
- 587 10. Buttner N, Geschwind D, Jen JC, Perlman S, Pulst SM, Baloh RW. Oculomotor phenotypes in autosomal
- 588 dominant ataxias. Archives of neurology. Oct 1998;55(10):1353-7. doi:10.1001/archneur.55.10.1353
- 589 11. Strupp M, Maul S, Konte B, et al. A Variation in FGF14 Is Associated with Downbeat Nystagmus in a
- 590 Genome-Wide Association Study. Cerebellum. Jun 2020;19(3):348-357. doi:10.1007/s12311-020-01113-x
- 591 12. Pellerin D, Danzi MC, Wilke C, et al. Deep Intronic FGF14 GAA Repeat Expansion in Late-Onset
- 592 Cerebellar Ataxia. N Engl J Med. Jan 12 2023;388(2):128-141. doi:10.1056/NEJMoa2207406

- 593 13. Rafehi H, Read J, Szmulewicz DJ, et al. An intronic GAA repeat expansion in FGF14 causes the
- 594 autosomal-dominant adult-onset ataxia SCA27B/ATX-FGF14. American journal of human genetics. Jun 1
- 595 2023;110(6):1018. doi:10.1016/j.ajhg.2023.05.005
- 596 14. Wilke C, Pellerin D, Mengel D, et al. GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history
- 597 progression and 4-aminopyridine treatment response. *Brain*. May 11 2023;doi:10.1093/brain/awad157
- 598 15. Pellerin D, Wilke C, Traschütz A, et al. Intronic FGF14 GAA repeat expansions are a common cause of
- 599 ataxia syndromes with neuropathy and bilateral vestibulopathy. J Neurol Neurosurg Psychiatry. 2023:jnnp-2023-
- 600 331490. doi:10.1136/jnnp-2023-331490
- 601 16. Claassen J, Spiegel R, Kalla R, et al. A randomised double-blind, cross-over trial of 4-aminopyridine for
- 602 downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol
- 603 Neurosurg Psychiatry. Dec 2013;84(12):1392-9. doi:10.1136/jnnp-2012-304736
- 604 17. Strupp M, Teufel J, Zwergal A, Schniepp R, Khodakhah K, Feil K. Aminopyridines for the treatment of
 605 neurologic disorders. *Neurol Clin Pract*. Feb 2017;7(1):65-76. doi:10.1212/cpj.00000000000321
- Seemann J, Traschütz A, Ilg W, Synofzik M. 4-Aminopyridine improves real-life gait performance in
 SCA27B on a single-subject level: a prospective n-of-1 treatment experience. *J Neurol*. 2023.
- Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: Interrater reliability of a neurologic
 rating scale. *Neurology*. Apr 12 2005;64(7):1261-2. doi:10.1212/01.wnl.0000156802.15466.79
- 610 20. Krafczyk S, Tietze S, Swoboda W, Valkovic P, Brandt T. Artificial neural network: a new diagnostic 611 for disorders posturographic tool of stance. Clin Neurophysiol. Aug 2006;117(8):1692-8. 612 doi:10.1016/j.clinph.2006.04.022
- 613 21. Strupp M, Kim JS, Murofushi T, et al. Bilateral vestibulopathy: Diagnostic criteria Consensus document of
 614 the Classification Committee of the Bárány Society. *J Vestib Res.* 2017;27(4):177-189. doi:10.3233/ves-170619
- 615 22. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical
- 616 research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine,
- 617 and the American Academy of Physical Medicine and Rehabilitation. *Neurology*. Jan 25 2005;64(2):199-207.
- 618 doi:10.1212/01.wnl.0000149522.32823.ea
- Bonnet C, Pellerin D, Roth V, et al. Optimized testing strategy for the diagnosis of GAA-FGF14
 ataxia/spinocerebellar ataxia 27B. *Scientific reports*. Jun 15 2023;13(1):9737. doi:10.1038/s41598-023-36654-8

- 621 24. Hengel H, Pellerin D, Wilke C, et al. As frequent as polyglutamine SCAs: SCA27B in a large German
- 622 autosomal dominant ataxia cohort. *Movement Disorders*. 2023;In Press
- 623 25. Pellerin D, Gobbo GD, Couse M, et al. A common flanking variant is associated with enhanced meiotic
- 624 stability of the *FGF14*-SCA27B locus. *bioRxiv*. 2023:2023.05.11.540430. doi:10.1101/2023.05.11.540430
- 625 26. Pellerin D, Iruzubieta P, Tekgül S, et al. Non-GAA Repeat Expansions in FGF14 are Likely Not
- 626 Pathogenic. Movement Disorders. 2023; In Press
- 627 27. Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. Oct 1
- 628 2015;526(7571):68-74. doi:10.1038/nature15393
- 629 28. Kheradmand A, Zee DS. Cerebellum and ocular motor control. *Frontiers in neurology*. 2011;2:53.
- 630 doi:10.3389/fneur.2011.00053
- 631 29. Graves TD, Jen JC. Progressive Vestibulocerebellar Syndromes. In: Bronstein A, ed. *Oxford Textbook of*
- 632 *Vertigo and Imbalance*. Oxford University Press; 2013:0.
- 633 30. Alviña K, Khodakhah K. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J
 634 *Neurosci.* May 26 2010;30(21):7258-68. doi:10.1523/jneurosci.3582-09.2010
- 635 31. Jayabal S, Chang HH, Cullen KE, Watt AJ. 4-aminopyridine reverses ataxia and cerebellar firing
 636 deficiency in a mouse model of spinocerebellar ataxia type 6. *Scientific reports*. Jul 6 2016;6:29489.
 637 doi:10.1038/srep29489
- 638 32. Bosch MK, Carrasquillo Y, Ransdell JL, Kanakamedala A, Ornitz DM, Nerbonne JM. Intracellular FGF14
- 639 (iFGF14) Is Required for Spontaneous and Evoked Firing in Cerebellar Purkinje Neurons and for Motor
- 640 Coordination and Balance. J Neurosci. Apr 29 2015;35(17):6752-69. doi:10.1523/jneurosci.2663-14.2015
- 641 33. Shakkottai VG, Xiao M, Xu L, et al. FGF14 regulates the intrinsic excitability of cerebellar Purkinje
- 642 neurons. *Neurobiology of disease*. Jan 2009;33(1):81-8. doi:10.1016/j.nbd.2008.09.019

643

644 Figure legends

645 Figure 1: Study flowchart of the recruitment of patients with idiopathic DBN

- 646 DBN: downbeat nystagmus.
- 647

648 Figure 2: Frequency of *FGF14* GAA repeat expansions in DBN syndromes

649 (A) Allele distribution of the FGF14 repeat locus in 170 patients with idiopathic DBN syndromes (340 650 chromosomes). The density plot shows allele size frequencies, with higher densities indicating greater frequencies. 651 The box-and-whisker plot above the graph shows the allele distribution. The box indicates the 25th percentile (first quartile), the median, and the 75th percentile (third quartile), and the whiskers indicate the 2.5th and 97.5th 652 653 percentiles. Outliers are represented by black dots. The dashed gray line and the shaded gray area indicate the so-654 called "intermediate" allele range of (GAA)200-249, and the dashed red line represents the pathogenic threshold of 655 $(GAA)_{>250}$ repeat units. (B) Percentage of patients carrying an FGF14 (GAA)_{>250} expansion (dark blue), an FGF14 656 (GAA)₂₀₀₋₂₄₉ allele (light blue), and an FGF14 (GAA)_{<200} allele (gray) in the subgroups with (1) pure DBN (0/7, 0/7, 657 and 7/7 patients, respectively), (2) DBN plus additional isolated cerebellar ocular motor signs (DBN+COM) (42/75, 658 10/75, and 23/75 patients), (3) DBN plus cerebellar ataxia (DBN+CA) (23/32, 2/32, and 7/32 patients), and (4) DBN 659 plus cerebellar ocular motor signs and/or ataxia and extracerebellar features (DBN+EC) (17/56, 8/56, and 31/56 660 patients). (C) Frequency of presenting symptoms in 81 patients with DBN carrying an *FGF14* (GAA)_{>250} expansion. 661 Data on presenting symptoms were missing for one patient. Patients may present with multiple symptoms at disease 662 onset. Visual disturbances include diplopia, oscillopsia, and visual blurring. (D) Weak inverse correlation between 663 size of the repeat expansion and age at disease onset in 74 patients carrying an FGF14 (GAA)_{>250} expansion for 664 whom information on age at onset was available (Pearson's r, -0.30; $R^2=0.09$; p=0.01). The gray area displays the 665 95% confidence interval. (E) UpSet plot showing co-occurrence of cerebellar ocular motor signs (COM), cerebellar 666 ataxia (CA), bilateral vestibulopathy (BVP), and neuropathy among 82 patients with DBN carrying an FGF14 667 $(GAA)_{\geq 250}$ expansion.

668

669 Figure 3: Phenotypic evolution in GAA-*FGF14*-related DBN syndromes

670 (A) Kaplan-Meier curve showing the probability of being disease free as a function of the age (years) for 74 patients 671 carrying an *FGF14* (GAA)_{≥ 250} expansion for whom age at onset was available. Median survival before occurrence of

672 disease was 67 years. The shaded gray area displays the 95% confidence interval around the probability estimate. 673 (B) Disease duration at last examination for patients carrying an FGF14 (GAA)_{>250} expansion with DBN plus 674 additional isolated cerebellar ocular motor signs (DBN+COM, n=36; median, 4.25 years), DBN plus cerebellar 675 ataxia (DBN+CA, n=21; median, 6 years), and DBN plus cerebellar ocular motor signs and/or ataxia and 676 extracerebellar features (DBN+EC, n=17; median, 9 years). Disease duration was significantly longer for patients 677 with extracerebellar features (Kruskal-Wallis test, p=0.014). (C) Temporal evolution of select phenotypic features 678 relative to the onset of gait impairment (dotted line). The solid black lines show the median time from onset of gait 679 impairment for each individual feature. (**D**) Occurrence of cerebellar atrophy on brain MRI (n=7), polyneuropathy 680 on nerve conduction studies (n=7), and BVP on caloric stimulation or vHIT (n=7) in relation to disease onset. BVP 681 occurred later in disease course compared to cerebellar ataxia and polyneuropathy (Kruskal-Wallis test, p=0.004). In 682 panels B and D, the individual between-group adjusted p values (q values) as per the Benjamini-Hochberg method 683 are shown in the graphs. Adjusted p values < 0.05 indicate statistically significant difference.

684

685 Figure 4: Progression of disability in GAA-FGF14-related DBN syndromes

686 (A) Cross-sectional progression of the functional impairment as assessed by the FARS functional disability stage 687 relative to disease duration (n=73 patients carrying an FGF14 [GAA]_{>250} expansion). The FARS functional stage 688 was not significantly associated with disease duration (Spearman's rho, 0.194; p=0.10). (B) Longitudinal intra-689 individual progression of functional impairment as assessed by the FARS functional disability stage relative to 690 disease duration (148 observations from 40 patients carrying an FGF14 [GAA]_{>250} expansion are shown). 691 Observations from the same patient are connected by a dotted line. The solid black line shows the average 692 progression of the FARS stage over disease duration across all patients as modelled by a linear mixed-effects model 693 accounting for disease duration as fixed effect and with random intercepts and random slopes. In both panels, only 694 FARS stages measured off 4-AP treatment are shown. Two patients who became wheelchair-dependent following a 695 hip fracture and a prolonged medical admission, respectively, are represented by orange squares in panel A and by 696 squares in panel B. These patients also carried alleles of 218 and 270 repeat units and 280 and 313 repeat units, 697 respectively.

698

699 Figure 5: Association of the rs72665334 variant with *FGF14* GAA expansions

700 (A) Diagram of the FGF14 gene, isoform 1b showing the location of the rs72665334 variant (GRCh38, 701 chr13:102,150,076) in relation to the $(GAA)_{n}$ (TTC)_n repeat locus in the first intron (GRCh38, chr13:102,161,575-702 102,161,726). The rs72665334 variant is located ~11kb 5' of the intronic GAA short tandem repeat. (B) Percentage 703 of patients with DBN carrying an FGF14 (GAA)_{≥ 250} expansion (n=35; dark blue), an FGF14 (GAA)_{$\geq 00-249$} allele 704 (n=9; light blue), and an FGF14 (GAA)_{<200} allele (n=29; gray) with the C|C, C|T, and T|T rs72665334 genotypes. 705 There was a significantly greater proportion of patients with a C|T or T|T genotype who carried an FGF14 706 (GAA)_{>250} expansion compared to an FGF14 (GAA)_{<200} allele (54% vs 14%; OR, 7.18; 95% CI, 1.91 to 34.43; 707 Fisher's exact test p=0.0014). (C) Frequency of the C|C, C|T, and T|T rs72665334 genotypes in 503 European 708 controls from the 1000 Genomes Project²⁷ and 72 patients with DBN carrying an FGF14 (GAA)_{>250} expansion 709 (n=35 from the idiopathic DBN cohort and n=37 from the French-Canadian cohort). The C|T and T|T genotypes 710 were significantly more frequent in patients with DBN carrying an FGF14 (GAA)_{≥250} expansion compared to 711 controls (46%, 33/72 vs 12%, 60/503; OR, 6.22; 95% CI, 3.51 to 11.02; Fisher's exact test, p=1.063e-10).

712

713 Figure 6: Treatment response to 4-aminopyridine

714 Open-label real-world treatment response data. Percentage of patients presenting (A) a clinician-reported response 715 and (B) a patient-reported response to 4-AP treatment in the subgroups with an FGF14 (GAA)_{>250} expansion (29/36) 716 and 29/49 patients, respectively), (GAA)₂₀₀₋₂₄₉ allele (4/5 and 3/5 patients), and (GAA)_{<200} allele (5/16 and 2/19 717 patients). Double-blind placebo-controlled clinical trial data. (C) Effect of 4-AP on the slow phase velocity (SPV) 718 of DBN in a randomized double-blind trial.¹⁶ Compared to baseline, the absolute value of the SPV significantly 719 decreased under 4-AP 60 min after the first dose and under daily treatment, but not under placebo. Note that all four 720 patients were randomized to receive active treatment first (= 4-AP) and placebo second. SPV during all three 721 measurements of the placebo phase was higher than at the baseline of the treatment phase. The improved values of 722 the SPV under 4-AP were in the range of the placebo values. (D) Treatment effect of 4-AP, illustrated by relative 723 reduction (improvement) of SPV as potential future trial outcome assessment. The genotype of the four patients was: 724 patient 1, 65 and 298 repeat units; patient 2, 44 and 354 repeat units; patient 3, 16 and 265 repeat units; patient 4, 725 280 and 313 repeat units. In panels C and D, the black line shows the mean value for all four patients at each time 726 point.

727

728 Figure 7: Effect of 4-aminopyridine on functional impairment

- 729 Longitudinal intra-individual progression of functional impairment while on and off 4-AP treatment as assessed by
- 730 the FARS functional disability stage relative to disease duration for (A-G) seven patients carrying an FGF14
- 731 (GAA)_{≥ 250} expansion and (**H-I**) two patients carrying an *FGF14* (GAA)₂₀₀₋₂₄₉ allele. FARS stages were invariably
- 132 lower while on 4-AP treatment for all nine patients, indicating an improvement in the level of disability. No patients
- 733 carrying an *FGF14* (GAA)_{<200} allele had FARS stages recorded while on and off 4-AP treatment.
- 734

735

736 <u>Table</u>

	FGF14 (GAA)>250	FGF14 (GAA)200-249	FGF14 (GAA)<200	FGF14 (GA	A) _{>250} vs	
	(n=82)	(<i>n</i> =20)	(<i>n</i> =68)	FGF14 (GA	FGF14 (GAA) < 200	
				p value	q value	
Male sex	44 (54%)	11 (55%)	40 (59%)	-	_	
Triplet repeat count of	324 (250-516)	234 (207-249)	37 (8-335)	-	-	
the larger allele*						
Age at disease onset	67 (30-81)	72 (45-84)	66 (17-88)	0.611	0.760	
Disease duration	6 (0-26.5)	4 (0-23)	4 (0-50)	0.180	0.407	
Age at last examination	73 (40-92)	79 (58-86)	72 (21-91)	0.346	0.554	
Positive family history	31/82 (38%)	4/20 (20%)	13/67 (19%)	0.019	0.097	
FARS disability stage	3 (1.5-5)	3 (1.5-4)	2 (1-4)	0.115	0.307	
History of falls	27/50 (54%)	8/14 (57%)	20/35 (57%)	0.827	0.882	
Regular use of walking	16/81 (20%)	4/19 (21%)	15/66 (23%)	0.688	0.760	
aid						
Symptoms			· ·			
Episodic symptoms	11/81 (14%)	0/19 (0%)	18/66 (27%)	0.059	0.173	
Gait impairment	81/81 (100%)	20/20 (100%)	68/68 (100%)	1.000	1.000	
Vertigo or dizziness	23/82 (28%)	10/20 (50%)	26/68 (38%)	0.222	0.442	
Visual disturbances	47/82 (57%)	8/20 (40%)	30/68 (44%)	0.140	0.344	
Fine motor impairment	12/80 (15%)	1/18 (6%)	12/66 (18%)	0.658	0.760	
Speech impairment	13/81 (16%)	4/19 (21%)	13/66 (20%)	0.665	0.760	
Clinical signs						
Impaired balance/gait	67/79 (85%)	13/19 (68%)	44/64 (69%)	0.027	0.108	
Cerebellar ocular						
motor signs						
- Gaze-evoked	57/82 (70%)	11/20 (55%)	42/67 (63%)	0.390	0.594	
nystagmus						
- Saccadic pursuit	80/81 (99%)	20/20 (100%)	59/67 (88%)	0.011	0.073	
- Dysmetric saccades	22/79 (28%)	6/20 (30%)	22/67 (33%)	0.588	0.760	
- Impaired VOR	64/74 (86%)	16/17 (94%)	23/46 (50%)	< 0.001	< 0.001	
suppression**						
Cerebellar ataxia						
- Ataxia of upper limbs	16/73 (22%)	1/14 (7%)	21/55 (38%)	0.051	0.163	
- Dysdiadochokinesia	15/71 (21%)	1/16 (6%)	14/54 (26%)	0.531	0.760	
- Dysarthria	12/80 (15%)	2/19 (11%)	12/63 (19%)	0.653	0.760	
Tremor of upper limbs	12/79 (15%)	2/18 (11%)	6/66 (9%)	0.318	0.536	
Neuropathy						
- Impaired vibration at	11/79 (14%)	6/18 (33%)	24/65 (37%)	0.002	0.018	
ankle ($\leq 3/8$)		-				
- Ankle hyporeflexia	20/79 (25%)	4/18 (22%)	29/65 (45%)	0.021	0.097	
Pyramidal tract signs	1/77 (1%)	0/18 (0%)	2/66 (3%)	0.595	0.760	
MRI						
Vermis atrophy	8/60 (13%)	1/11 (9%)	10/47 (21%)	0.307	0.536	
Cerebellar hemisphere	5/60 (8%)	0/11 (0%)	8/47 (17%)	0.235	0.442	
atrophy						
Supratentorial atrophy	5/60 (8%)	2/10 (20%)	4/47 (9%)	1.000	1.000	
Brainstem atrophy	0/60 (0%)	0/10 (0%)	2/47 (4%)	0.191	0.407	
Nerve conduction studies						
Axonal neuropathy 7/15 (47%) 3/5 (60%) 10/11 (91%) 0.036 0.129						
Vestibular function evalu	uation – caloric stimulatio	n, vHIT, rotatory chair		0.553		
Bilateral vestibulopathy	8/79 (10%)	3/18 (17%)	20/62 (32%)	0.001	0.018	
VOR gain on vHIT in	0.44 (±0.10)	0.21	0.18 (±0.17)	0.006	0.0496	
$BVP - mean (\pm SD)$						

737

738 Table 1: Characteristics and discriminative features of GAA-*FGF14*-related DBN syndromes

739	Unless specified, data are reported as median (range). Bold values indicate statistically significant adjusted p values
740	(q values) below the 0.05 threshold as per the Benjamini-Hochberg method. Data on age at onset were missing for
741	eight patients in the $(GAA)_{\geq 250}$ group, three patients in the $(GAA)_{200-249}$ group, and 10 patients in the $(GAA)_{<200}$
742	group.
743	
744	*The FGF14 (GAA) _{≥ 250} group includes a patient carrying biallelic GAA repeat expansions (280 and 313 repeat
745	units). The $FGF14$ (GAA) _{<200} group includes two patients carrying a likely non-pathogenic (GAAGGA) _n expansion
746	(335 and 319 triplet repeat units equivalent, respectively). **In patients without bilateral vestibulopathy.
747	
748	Abbreviations: BVP: bilateral vestibulopathy; FARS: Friedreich Ataxia Rating Scale; vHIT: video head impulse

- 749 test; VOR: vestibulo-ocular reflex.
- 750













